Mr Raffy Kazandjian, President & Chief Executive Officer

Raffy brings over 25 years of experience in the biotechnology and venture-capital industry. Former President of CDC-Innovation, a French venture-capital fund, from 1998 to 2002, he raised over €250 million of capital, and was responsible for €300 million in funds under management. In his career, Raffy has supervised over 70 investments in technology start-ups, held numerous board positions, and assisted several biotech companies, including companies such as Cellectis in their financing and growth strategies. Raffy holds an engineering degree from the Chemistry Engineering School of Paris (ENSCP), and is a graduate from MIT (MS’85) and from the European Business School INSEAD (MBA’90).

Francine Behar-Cohen, MD, PhD, Founder & Chief Scientific Officer

Francine founded Eyevensys in December 2008. From 2013 to 2016, she was the Chief Medical Officer of the Gonin Lausanne Ophthalmology Hospital in Switzerland. She is Professor of Ophthalmology at Paris Descartes University (France), Head of the Department of Ophthalmology of Hôtel-Dieu – University of Paris Descartes Hospital, and Director of the “Physiopathology of Ocular Diseases” lab at the Cordeliers INSERM Centre. She has authored over 164 publications since 1999. Very entrepreneurially oriented, Francine also founded Eyegate Pharma in 1997.

Dr Ronald Buggage, Chief Medical Officer

Dr Buggage brings more than 14 years experience from both large pharma and biotech companies having worked in senior development positions in the US and Europe.

He began his career as Staff Clinician and Director of the Ocular Immunology and Uveitis Program at the prestigious National Eye Institute of the National Institutes of Health in Bethesda, Maryland, where he led numerous clinical trials in subjects with retinal disease. In 2004, he joined Pfizer’s laboratories, becoming Worldwide Medical Director for Research & Development. He then joined the Novartis group as New Product Executive Medical Director within the Neuroscience and Ophthalmology Franchise, where he was responsible for defining and executing the global development strategy for ophthalmic therapies.

In 2010 Dr Buggage was appointed Chief Scientific Officer of Novagali Pharma in France where he was responsible for the overall global clinical and regulatory strategy creation and execution. Most recently he was Division Medical Officer at Sanofi’s Ophthalmology Unit in Paris.

Dr. Thierry Bordet, Preclinical Development Director

Thierry brings more than 15 years experience in the biotechnological sector having managed drug discovery and drug development programs for small molecules, gene therapies, cell-based therapies and regenerative medicine.

Earlier in his career, as Scientific Project Leader in drug discovery programs for motor neuron disorders and subsequently as Head of CNS Pharmacology at Trophos, Thierry played a key role in the identification and preclinical development of olesoxime, the company’s lead compound which proved to be active in a phase 3 clinical trial for Spinal Muscular Atrophy. After Trophos acquisition by Roche, he became the Director of Preclinical Development at the Biotherapies Institute for Rare Diseases in Evry (France) where he conducted development strategies for advanced therapy medicinal products for various indications, including Crigler-Najjar syndrome and retinitis pigmentosa.

Thierry is a graduate from Ecole Normale Supérieure de Lyon (ENS Lyon) and holds a Ph.D in Microbiology and Virology from Pierre and Marie Curie University (Paris VI).